A detailed history of Schroder Investment Management Group transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 1,906,602 shares of GILD stock, worth $168 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,906,602
Previous 1,584,240 20.35%
Holding current value
$168 Million
Previous $116 Million 12.72%
% of portfolio
0.15%
Previous 0.14%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $20.4 Million - $23.5 Million
322,362 Added 20.35%
1,906,602 $131 Million
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $4.46 Million - $5.44 Million
-62,349 Reduced 3.79%
1,584,240 $116 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $9.72 Million - $11 Million
132,679 Added 8.76%
1,646,589 $133 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $12.3 Million - $13.5 Million
166,731 Added 12.38%
1,513,910 $113 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $15.1 Million - $17.3 Million
-198,968 Reduced 12.87%
1,347,179 $104 Million
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $14.5 Million - $16.5 Million
-187,464 Reduced 10.81%
1,546,147 $128 Million
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $3.89 Million - $5.58 Million
-62,391 Reduced 3.47%
1,733,611 $149 Million
Q3 2022

Nov 10, 2022

SELL
$59.54 - $68.01 $1.7 Million - $1.94 Million
-28,515 Reduced 1.56%
1,796,002 $111 Million
Q2 2022

Aug 11, 2022

BUY
$57.72 - $65.01 $51.2 Million - $57.7 Million
887,812 Added 94.78%
1,824,517 $114 Million
Q1 2022

May 16, 2022

BUY
$57.92 - $72.58 $6.41 Million - $8.03 Million
110,647 Added 13.39%
936,705 $55.9 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $3 Million - $3.41 Million
-46,256 Reduced 5.3%
826,058 $60 Million
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $30.6 Million - $33 Million
-452,143 Reduced 34.14%
872,314 $60.9 Million
Q2 2021

Aug 13, 2021

SELL
$63.47 - $69.35 $23.5 Million - $25.7 Million
-370,982 Reduced 21.88%
1,324,457 $91.2 Million
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $36.3 Million - $41.4 Million
-604,259 Reduced 26.28%
1,695,439 $110 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $11 Million - $12.6 Million
194,874 Added 9.26%
2,299,698 $134 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $21.2 Million - $26.6 Million
340,843 Added 19.32%
2,104,824 $131 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $6.06 Million - $7.04 Million
83,780 Added 4.99%
1,763,981 $136 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $73.5 Million - $94.2 Million
-1,174,030 Reduced 41.13%
1,680,201 $131 Million
Q4 2019

Feb 11, 2020

BUY
$61.62 - $67.78 $46.9 Million - $51.6 Million
761,583 Added 36.39%
2,854,231 $185 Million
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $19.8 Million - $21.9 Million
-317,240 Reduced 13.16%
2,092,648 $132 Million
Q2 2019

Aug 08, 2019

SELL
$61.87 - $69.38 $21.8 Million - $24.4 Million
-352,393 Reduced 12.76%
2,409,888 $163 Million
Q1 2019

May 14, 2019

SELL
$62.53 - $70.05 $3.27 Million - $3.67 Million
-52,351 Reduced 1.86%
2,762,281 $180 Million
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $31.4 Million - $41 Million
-518,710 Reduced 15.56%
2,814,632 $176 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $4.08 Million - $4.52 Million
57,257 Added 1.75%
3,333,342 $257 Million
Q2 2018

Aug 13, 2018

BUY
$64.88 - $75.68 $26.9 Million - $31.4 Million
415,334 Added 14.52%
3,276,085 $230 Million
Q1 2018

May 11, 2018

SELL
$72.84 - $88.8 $20.5 Million - $25 Million
-282,016 Reduced 8.97%
2,860,751 $216 Million
Q4 2017

Feb 09, 2018

SELL
$71.15 - $83.52 $35.3 Million - $41.5 Million
-496,650 Reduced 13.65%
3,142,767 $225 Million
Q3 2017

Nov 09, 2017

BUY
$72.11 - $85.47 $262 Million - $311 Million
3,639,417
3,639,417 $294 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.